中国鲍曼不动杆菌感染诊治与防控专家共识

[9] Lenie D, Alexandr N, Harald S. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol, 2007, 5:939-951.
[10] 杨启文，王辉，徐英春，等.腹腔感染细菌流行病学调查.中华普通外科学文献,2009,3:427-432.
[11] Falagas ME, Karveli EA, Kelesidis I et al. Community-acquired Acinetobacter infections. Eur J Clin Microbiol Infect Dis,2007, 26:857-868.
[12] Galani I, Flora K, Maria S, et al. Colistin susceptibility testing by Etest and disk diffusion methods. Int J Antimicrob Agents, 2008, 31:434-439.
[13] Zhou H, Zhang T, Yu D, et al. Genomic analysis of the multi-drug resistant Acinetobacter baumannii strain MDR-ZJ06 widely spread in China. Antimicrob Agents Chemother ,2011, 55:4506-4512.
[14] Bergogne E, Towner KJ. Acinetobacter spp. as Nosocomial Pathogens: Microbiological, Clinical, and Epidemiological Features. Clin Microbiol Rev, 1996, 9:148-165.
[15] La Scola B, Gundi VA, Khamis A, et al. Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species. J Clin Microbiol, 2006, 44:827-832.
[16] Turton JF, Woodford N, Glover J, et al. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol, 2006, 44:2974-2976.
[17] Ecker JA, Massire C, Hall TA, et al. Identification of Acinetobacter species and genotyping of Acinetobacter baumannii by multilocus PCR and mass spectrometry. J Clin Microbiol, 2006, 44:2921-2932.
[18] Higgins PG, Wisplinghoff H, Krut O, Seifert H. A PCR based method to differentiate between Acinetobacter baumannii and Acinetobacter genomic species 13TU. Clin Microbiol Infect, 2007, 13:1199-1201.
[19] Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement. Wayne, Pa. Clinical and Laboratory Standards Institute, 2011:M100-S21.
[20] Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis, 2010, 51:79-84.
[21] Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis, 2010, 23: 332-339.
[22] Neonakis IK, Spandidos DA, Petinaki E. Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents, 2011, 37: 102-109.
[23] Jian Li, Craig RR, Roger LN, et al. Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother, 2006, 50: 2946-2950.
[24] Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother, 2006, 50: 3479-3484.
[25] Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother, 2007, 59:772-774.
[26] Lee NY, Wang CL, Chuang YC, et al. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy, 2007, 27:1506-1511.
[27] Kiffer CR, Sampaio JL, Sinto S, et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis, 2005, 52:317-322.
[28] Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect, 2008,14:816-827.
[29] Sopirala MM , Mangino JE , Gebreyes WA , et al. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother , 2010,54:4678-4683.
[30] Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents, 2009,34: 8.e1-9.
[31] Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother, 2006, 57:573-576.
[32] Jennifer HM, Marina H, Paul H. Colistin Resistance in Acinetobacter baumannii Is Mediated by Complete Loss of Lipopolysaccharide Production. Antimicrob Agents Chemother, 2010, 54:4971-4977.
[33] Luna CM, Aruj PK. Nosocomial Acinetobacter pneumonia. Respirology , 2007, 12:787-791.
[34] Towner KJ. Acinetobacter: an old friend, but a new enemy. J Hosp Infect, 2009, 73:355-363.
[35] Hilmar W, Michael B, Edmond MA, et al. Nosocomial Bloodstream Infections Caused by Acinetobacter Species in United States Hospitals: Clinical Features, Molecular Epidemiology, and Antimicrobial Susceptibility. Clin Infect Dis, 2000, 31:690-697.
[36] Trottier V, Namias N, Pust DG, et al. Outcomes of Acinetobacter baumannii infection in critically ill surgical patients. Surg Infect (Larchmt), 2007, 8:437-443.
[37] Rodriguez-Bano J, Cisneros JM, Fernandez-Cuenca F, et al. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol, 2004, 25: 819-824.
[38] Sanford JP (桑福德)著, 范宏伟译. 热病：《桑福德抗微生物治疗指南》(新译第39版). 中国协和医科大学出版社,2011:230-256.
[39] Mermel LA, Allon M, Bouza E, et al. Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis, 2009, 49:1-45.
[40] 中华医学会重症医学分会.血管内导管相关感染的预防与治疗指南(2007).中国实用外科杂志,2008, 28：413-421.
[41] Lemuel LDent, Dana RM, Siddharth P, et al. Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infectious Diseases,2010, 10:196.                                                                                                                  [42] Solomkin JS , Mazuski JE , Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis , 2010,50:133-164.
[43] Akkoyun S, Kuloglu F, Tokuc B. Etiologic agents and risk factors in nosocomial urinary tract infections. Mikrobiyol Bul,2008, 42:245-254.
[44] Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis , 2010, 50:625-663.
[45] Tenke P, Kovacs B, Bjerklund Johansen TE, et al. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int J Antimicrob Agents,2008, 31:S68-S78.
[46] Petersen K, Riddle MS, Danko JR, et al. Trauma-related infections in battlefield casualties from Iraq. Ann Surg,2007, 245:803-811.